TScan Therapeutics

TCRXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$52.032 M

$0.80 +4.32%

Close of 7 Aug 2026

Revenue

$10.3M

#3164 by revenue

Earnings

-$129.8M

Loss-making

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#124Inmune BioINMB$55.4M
#125MiNK TherapeuticsINKT$54.6M
#126TScan TherapeuticsTCRX$52.0M
#127OKYO PharmaOKYO$50.4M
#128Instil BioTIL$50.3M

Where these numbers come from

Share counts and financials for TScan Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.